01.05.2024 - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced its strategic plans for fiscal year 2025, beginning May 1, including for sebetralstat, the Company’s investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment . Seite 1
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) rose 6.8% on Wednesday . The stock traded as high as $12.13 and last traded at $12.12. Approximately 71,232 shares traded hands during trading, a decline of 90% from the average daily volume of 700,371 shares. The stock had previously closed at $11.35. Wall Street Analysts Forecast […]
KalVista Pharmaceuticals, Inc : KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research report issued on Wednesday, Benzinga reports. They presently have a $35.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective suggests a potential upside of 191.67% from the stock’s […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) rose 6.8% on Wednesday . The stock traded as high as $12.13 and last traded at $12.12. Approximately 71,232 shares traded hands during trading, a decline of 90% from the average daily volume of 700,371 shares. The stock had previously closed at $11.35. Wall Street Analysts Forecast […]